Teplizumab Prevention Study Chair Kevan Herold, M.D., Yale University, presented first-of-a-kind findings showing that teplizumab delayed type 1 diabetes a median of 2 years in children and adults at high risk. Findings were also simultaneously published in the New England Journal of Medicine 

Brenda Bradfield, BSN, CDE, works on the frontlines of type 1 diabetes (T1D) research at the Barbara Davis Center for Diabetes at the University of Colorado Anschutz Medical Campus.

Elliot, a 17-year-old from a small village outside Bristol, recently completed treatment in the Abatacept Prevention Study. He is the first person in the United Kingdom (UK) to do so.